louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05400083: Prevention of Incisional Hernia With Biosynthetic Mesh at the Site of Temporary Ileostomy Closure (PRINCESS)
Official title: Prevention of Incisional Hernia With Biosynthetic Mesh at the Site of Temporary Ileostomy Closure
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Incisional Hernia
Lead sponsor: Federico II University
Sponsor class: OTHER
First posted: 2022-06-01
Enrollment: 203
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: General and teaching hospitals

Brief summary: Prophylactic mesh reinforcement of the abdominal wall at the site of temporary ileostomy closure is effective in preventing postoperative incisional hernia.

This prospective, multicenter, observational study will evaluate performance of Phasix biosynthetic mesh when used to reinforce fascial closure .


Eligibility criteria: Inclusion Criteria:

* Subjects will be informed about the study, and will have read; understood and signed the informed consent
* Subjects of either gender that are at least the age of 18 years
* Subjects will be undergoing ileostomy reversal with retromuscular placement technique of the Phasix biosynthetic mesh reinforcement

Exclusion Criteria:

* Subjects who, in the surgeon's opinion, would have a difficult time comprehending or complying with the requirements of the study
* Subjects with parastomal hernia or midline incisional hernia
* Subjects who required midline laparotomy during ileostomy reversal

Primary outcomes:
measure: Incisional hernia rate
timeFrame: at 24 months
Secondary outcomes:
measure: Early and Long-term Complication Rates
timeFrame: after surgery to 24 months
measure: Postoperative pain
timeFrame: after surgery to 24 months
measure: Quality of life by Carolinas Comfort Scale (CCS) and Euro-Qol 5D-5L questionnaires
timeFrame: after surgery to 24 months
measure: Budget Impact Analysis
timeFrame: after surgery to 24 months
Other outcomes:
Locations:
city: Naples
country: Italy
facility: Minimally Invasive General and Oncologic Surgery Unit - Univesity of Naples Federico II
Study officials:
References:
Clinical trial NCT01386983: Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment
Official title: Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prostatic Hyperplasia
Keywords: Enlarged prostate, 5-alpha-reductase inhibitor, alpha-blocker, acute urinary retention, surgery, early, costs
benign prostatic hyperplasia
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2011-07-01
Enrollment: 332
Sex: MALE
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study will identify eligible patient data between April 1, 2000, and December 31, 2007, and allows for patient data to be followed for 3 months prior to and up to 1 year following index prescription date.

Brief summary: This retrospective study aims to assess the clinical and economic impact of early initiation of 5-alpha-reductase inhibitor (5ARI) therapy in patients with enlarged prostate (EP) receiving 5ARI monotherapy or combination therapy with an alpha-blocker (AB) compared to late initiation of 5ARI therapy in patients receiving combination therapy. The Henry Ford Health System databases will be utilized for this study (2000-2008).


Eligibility criteria: Inclusion Criteria:

* Males
* aged 50 years or older
* medical claim of EP
* prescription claim(s) for either a 5ARI or both 5ARI and AB (provided both are within 180 days of index date)
* continuously eligible for 3 months prior to and at least 5 months after their index prescription date.

Exclusion Criteria:

* Patients with prostate or bladder cancer
* any prostate-related surgical procedure within 5 months of index date
* prescription claim for finasteride indicative of male pattern baldness; AB monotherapy only; initiation of 5ARI occurring more than 180 days after initiation of AB

Primary outcomes:
measure: Number of Participants With Clinical Progression
timeFrame: 3 months prior to and 12 months following index date
Secondary outcomes:
measure: Dollar Amount of Enlarged Prostate (EP)-Related Medical Costs Incurred Per Month
timeFrame: 3 months prior to and 12 months following index date
Other outcomes:
Locations:
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT00876083: PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination
Official title: Post-marketing Surveillance Study Ultravist®-IMAGE IoproMide (UltrAvist®) to Gain Further Information on Tolerability and Safety in X-ray Examination
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diagnostic Imaging
Keywords: Drug utilization review
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2009-04-06
Enrollment: 44920
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will consist of female and male patients who require an X-ray examination with contrast enhancement. Physicians should consult the full prescribing information for Ultravist before enrolling patients and familiarize themselves with the safety information in the product package label.

Brief summary: The purpose of this study is to obtain data on the safety and efficacy of Ultravist application in usual daily use.The radiologist will administer the contrast medium to the patient as he/she would have done without the study. No other examinations will be performed than would have been done routinely.


Eligibility criteria: Inclusion Criteria:

* Patients with indication for an X-ray examination and for whom the radiologist has decided to use the contrast medium Ultravist.

Exclusion Criteria:

* No exclusion criteria besides the contraindications for the use of Ultravist as mentioned in the product information.

Primary outcomes:
measure: Occurrence of adverse events
timeFrame: During and after Ultravist application on the day of examination
Secondary outcomes:
measure: General contrast quality in the region of interest as assessed by physicians
timeFrame: On the day of examination
Other outcomes:
Locations:
city: Many Locations
country: Bosnia and Herzegovina
city: Many Locations
country: China
city: Many Locations
country: Germany
city: Many Locations
country: Hungary
city: Many Locations
country: Indonesia
city: Many Locations
country: Iran, Islamic Republic of
city: Many Locations
country: Italy
city: Many Locations
country: Korea, Republic of
city: Many Locations
country: Malaysia
city: Many Locations
country: Moldova, Republic of
city: Many Locations
country: Pakistan
city: Many Locations
country: Philippines
city: Many Locations
country: Poland
city: Many Locations
country: Romania
city: Many Locations
country: Russian Federation
city: Many Locations
country: Saudi Arabia
city: Many Locations
country: Singapore
city: Many Locations
country: Taiwan
city: Many Locations
country: Thailand
city: Many Locations
country: Ukraine
city: Many Locations
country: Vietnam
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT05704283: 3D Ultrasound for the Imaging of Lymph Nodes in Patients with Breast Cancer
Official title: 3D Ultrasound Imaging of the Axillary Lymph Nodes
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: EARLY_PHASE1
Conditions: Breast Carcinoma
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
name: National Institute for Biomedical Imaging and Bioengineering (NIBIB)
First posted: 2023-01-30
Enrollment: 80
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This early phase I studies how well a new 3D ultrasound (3D-US) imaging technology works in evaluating lymph nodes in patients with breast cancer. Ultrasound uses high-frequency sound waves to generate images of the body.

Detailed description: PRIMARY OBJECTIVES:

I. Conducting a pilot study to optimize the in vivo performance of the newly developed three-dimensional (3D)-ultrasound (US) technology.

II. Evaluate the performance of the new 3D-US technique in differentiating benign from malignant lymph nodes in patients.

III. Compare the performance of the new 3D-US method with conventional two-dimensional (2D)-US for localizing the clipped lymph nodes.

OUTLINE:

Patients undergo 3D-US on study. Patients who have a lymph node clip placed and undergoing neoadjuvant chemotherapy undergo imaging of the clipped node before surgery.

Eligibility criteria: Inclusion Criteria:

* Patients with lymph node biopsy or lymph node clip placement as per routine clinical care.
* Age of 18 or older.

Exclusion Criteria:

* Vulnerable subjects such as prisoners and adults lacking capacity to consent.

Primary outcomes:
measure: Lymph node diagnosis by radiologist (benign or malignant) (Aim 2)
timeFrame: Up to 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic in Rochester
name: Shigao D Chen, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00980083: GLP-1 - Regulatory Mechanism of Postprandial Glycemia
Official title: Endogenous GLP-1 Regulates Postprandial Glycaemia in Human: Relative Contributions of Insulin, Glucagon, and Gastric Emptying
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Subjects
Gastric Emptying
Keywords: GLP-1
exendin(9-39)
gastric emptying
incretin
human
Lead sponsor: Ludwig-Maximilians - University of Munich
Sponsor class: OTHER
First posted: 2009-09-18
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Synthetic GLP-1 lowers postprandial (pp) glycemia by stimulating insulin, inhibiting glucagon, and delaying gastric emptying. However, the effects of the endogenous peptide are largely unknown. Using the specific GLP-1 receptor antagonist exendin(9-39)amide (Ex(9-39)) the investigators recently showed that GLP-1 released during intestinal meal perfusion acts as an incretin hormone and as an enterogastrone. As the relative contributions of these effects to controll postprandial glycemia are unclear, the investigators used Ex(9-39) to investigate the mechanisms of action of GLP-1 after an oral meal in humans.

Detailed description: Two experiments were performed in random order in 12 healthy subjects. After a 50-min basal period subjects ingested a 412 kcal mixed semisolid meal containing 30g oatmeal, labelled with 99mTc-Sn-colloid. Gastric emptying was measured by high-resolution scintigraphy until 210 min after meal ingestion. Saline (SAL) or Ex(9-39) at 900 pmol/kg/min was intravenously infused during the two experiments. In addition, in 6 of the 12 subjects gastric motility was measured by antroduodenal manometry and gastric barostat. AUC: pp incremental area under the curve. Lag period (LP): time to 10% emptying.

Eligibility criteria: Inclusion Criteria:

* Healthy subject
* \>=18 years of age
* No medication

Exclusion Criteria:

* Acute disease
* Metabolic disease
* On medication
* Pregnancy, breast feeding
* Gastrointestinal surgery
* Dyspeptische Symptome (Völlegefühl, Blähungen, abdominelle Schmerzereignisse, Übelkeit, Erbrechen, Sodbrennen)
* Teilnahme an einer klinischen Studie in den vergangenen 6 Monaten

Primary outcomes:
measure: postprandial blood glucose levels
timeFrame: -50 min until 210 min after meal intake
Secondary outcomes:
measure: gastric emptying rate
timeFrame: 0-210min
measure: plasma levels of glucagon, insulin
timeFrame: -50min until 210 min
Other outcomes:
Locations:
city: Munich
country: Germany
facility: Department of Internal Medicine II, University of Munich
Study officials:
affiliation: University of Munich, Department of Internal Medicine II, Munich, Germany
name: Joerg Schirra, Prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04055883: Clinical Study to Evaluate Efficacy and Safety of DA-1229 in Patients With CAVD
Official title: A Multicenter, Double-blind, Placebo-controlled, Stratified-randomized, Parallel, Therapeutic Exploratory Clinical Study to Evaluate the Efficacy and Safety of DA-1229 in Patients With Calcific Aortic Valve Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Calcific Aortic Valve Disease
Lead sponsor: Dong-A ST Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2019-08-14
Enrollment: 228
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study will evaluate the efficacy and safety of DA-1229 in patients with calcific aortic valve disease.


Eligibility criteria: Inclusion Criteria:

* Adult male and female subjects of ages in the range over 19
* The subjects whose echocardiography or heart CT result meets the criterion in the screening period or 4 weeks before screening visit

  * Criterion : 2.0m/s ≤ peak aortic-jet velocity \< 4.0m/s or aortic valve calcium score ≥300AU
* The subjects completely understood the clinical trial through detailed explanation presented, determined to participate in the clinical trial spontaneously, and agreed to observe precautions suggested thereby through written consent

Exclusion Criteria:

* The cause of CAVD is niether degenerative nor bicuspid aortic valve
* The subjects who have other aortic valve disease as other clinically significant aortic insufficiency or mitral disease
* The subjects who had an aortic valve operation or are expected to need aortic valve operation

Primary outcomes:
measure: aortic valve calcium volume change
timeFrame: 96 weeks
Secondary outcomes:
measure: aortic valve calcium volume change
timeFrame: 48 weeks
measure: aortic valve calcium score change
timeFrame: 48 weeks, 96 weeks
measure: aortic valve calcium volume change percent
timeFrame: 48 weeks, 96 weeks
Other outcomes:
Locations:
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Bundang-gu
city: Gwangju
country: Korea, Republic of
facility: Chonnam National University Hospital
state: Donggu
city: Seoul
country: Korea, Republic of
facility: Gangnam Severance Hospital
state: Gangnam-gu
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
state: Gangnam-gu
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
state: Jongno-gu
city: Daegu
country: Korea, Republic of
facility: Kyeongpook National University Hospital
state: Jung-gu
city: Daejeon
country: Korea, Republic of
facility: Chungnam National University Hospital
state: Jung-gu
city: Yangsan
country: Korea, Republic of
facility: Pusan National University Yangsan Hospital
state: Mulgeum-eup
city: Seoul
country: Korea, Republic of
facility: Severance
state: Seodaemun-gu
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
state: Songpa-gu
Study officials:
References:
Clinical trial NCT04457661: Evaluation of the Alcohol Elimination Effect of TCI711 Probiotic (Bacillus Coagulans) on Adult Individuals
Official title: Evaluation of the Alcohol Elimination Effect of TCI711 Probiotic (Bacillus Coagulans) on Adult Individuals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breath Alcohol Level
Lead sponsor: TCI Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2020-07-07
Enrollment: 19
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Investigating the possibility of using Bacillus coagulans TCI711 to improve the efficiency of alcohol removal in adult individuals.


Eligibility criteria: Inclusion Criteria:

* Healthy volunteers aged between 20 to 60.
* Systolic pressure below 140
* Score of C-CAGE Questionnaire below 8 (male)/6 (female)
* Prohibiting other supplements before 2 weeks of the study and during the study
* Prohibiting alcohol drinks before 24 hours of the study
* Prohibiting caffeine drinks before 12 hours of the study

Exclusion Criteria:

* Alcohol or drug allergy
* Liver, kidney, cardiovascular, or chronic diseases
* Other severe disorders
* Hypertension
* Pregnancy or lactation
* Already involved in clinical testing
* Other supplements

Primary outcomes:
measure: Breath Alcohol Level
timeFrame: 5 minutes after drinking a certain volume of whisky
measure: Breath Alcohol Level
timeFrame: 15 minutes after drinking a certain volume of whisky
measure: Breath Alcohol Level
timeFrame: 30 minutes after drinking a certain volume of whisky
measure: Breath Alcohol Level
timeFrame: 60 minutes after drinking a certain volume of whisky
measure: Breath Alcohol Level
timeFrame: 90 minutes after drinking a certain volume of whisky
measure: Breath Alcohol Level
timeFrame: 120 minutes after drinking a certain volume of whisky
measure: Breath Alcohol Level
timeFrame: 150 minutes after drinking a certain volume of whisky
measure: Breath Alcohol Level
timeFrame: 180 minutes after drinking a certain volume of whisky
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei City
country: Taiwan
facility: GeNext
Study officials:
References:
Clinical trial NCT00399061: Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms
Official title: Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Dry Eye
Lead sponsor: Innovative Medical
Sponsor class: INDUSTRY
First posted: 2006-11-14
Enrollment: 55
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy of Optive versus Systane used concomitantly with topical cyclosporine for the treatment of dry eye.


Eligibility criteria: Inclusion Criteria:

* · Males or females \> 18 years old

  * Score of at least 2 and no more than 4 on the SESOD at the initial screening visit (mild to severe patients)
  * At least Grade 2 conjunctival staining
  * Likely to complete all study visits and able to provide informed consent

Exclusion Criteria:

* · Prior unsuccessful use of topical cyclosporine (defined as patients taking it at least 3 months and saw no improvements)

  * Current use of topical cyclosporine
  * Known contraindications to any study medication or ingredients
  * Female of child bearing potential not using reliable methods of birth control, or pregnant or lactating females.
  * Planned use of contact lenses (unless discontinued use ³ 30 days prior to randomization)
  * Active ocular diseases or uncontrolled systemic disease (blepharitis patients that are actively being treated or disease that is uncontrollable)
  * Ocular surgery within the past 3 months,
  * Active ocular allergies

Primary outcomes:
measure: Efficacy
timeFrame: 1 yr 3 months
Secondary outcomes:
measure: Dry eye symptoms
timeFrame: 1yr 3 months
Other outcomes:
Locations:
city: Slingerlands
country: United States
facility: Dr. Schultze
state: New York
Study officials:
affiliation: Slingerlands Medical Building
name: Robert Schultze, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00828061: A Study of the Effects of Single Dose Corticosteroids on Response to Allergens
Official title: A Randomized Clinical Trial to Study the Effects of Single Dose of Corticosteroid on Response to Nasal Allergen Challenge in Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Allergic Rhinitis
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2009-01-23
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: This study will investigate whether changes in inflammatory mediators produced by the nose after exposure to an allergen can be used to evaluate the anti-inflammatory effects of novel drugs for the treatment of allergic asthma.


Eligibility criteria: Inclusion Criteria:

* Patient is allergic to Timothy grass pollen
* Female patients have a negative pregnancy test and agree to use birth control throughout the study
* Male patients agree to use birth control throughout the study
* Patient has been a nonsmoker for at least 6 months
* Patient agrees to avoid the use of aspirin and other Non-steroidal anti-inflammatory drugs (NSAIDs) throughout study

Exclusion Criteria:

* Patient is breastfeeding
* Patient has any respiratory disease other than mild stable asthma that does not require treatment
* Patient consumes more than 3 alcoholic beverages per day
* Patient consumes more than 6 caffeinated beverages per day
* Patient has had major surgery or has donated or lost 1 unit of blood within 4 weeks of screening
* Patient has severe allergies

Primary outcomes:
measure: Fold Change From Baseline at Hour 8 in Interleukin 5 (IL-5) Concentration
timeFrame: Baseline and Hour 8 post nasal allergen challenge
Secondary outcomes:
measure: Change From Baseline at Hour 8 in the Percent of Total Cells That Are Eosinophils
timeFrame: Baseline and Hour 8 post nasal allergen challenge
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Leaker BR, Malkov VA, Mogg R, Ruddy MK, Nicholson GC, Tan AJ, Tribouley C, Chen G, De Lepeleire I, Calder NA, Chung H, Lavender P, Carayannopoulos LN, Hansel TT. The nasal mucosal late allergic reaction to grass pollen involves type 2 inflammation (IL-5 and IL-13), the inflammasome (IL-1beta), and complement. Mucosal Immunol. 2017 Mar;10(2):408-420. doi: 10.1038/mi.2016.74. Epub 2016 Sep 28.
Clinical trial NCT01709461: Continuation Treatment Protocol for Patients Who Participated in the Adagio TVP 1012/501 Clinical Trial
Official title: Continue Providing Care for Patient Who Participated in the Adagio TVP 1012/501 Clinical Trial
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Parkinson Disease
Lead sponsor: Rabin Medical Center
Sponsor class: OTHER
First posted: 2012-10-18
Enrollment: 12
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: subjects who took part in the TVP 1012/501 clinical trial and willing to contiue receiving Rasgiline Mesylate.

Brief summary: the purpose of the study is to extend the use of Rasagelin Mesylate 1mg per day by subjects who participated in the Adagio TVP 1012/501 according to form 4a for additional three years.


Eligibility criteria: Inclusion Criteria:

* subjects who are willing to contiue this treatment.
* subjects who took part in the TVP 1012/501 clinical trail.

Exclusion Criteria:

* subjects who didn't take part in the TVP 1012/501 clinical trail.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Petach Tiqva
country: Israel
facility: Rabin Medical Center Beilinson Campus
state: Hamerkaz
Study officials:
References: